Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016406 · ClinicalTrials.gov registry record · Phase 3
S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 399
- Enrollment target
NCT00016406 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 399 participants.
The verdict
NCT00016406, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 399 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without filgrastim in treating breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combining doxorubicin, cyclophosphamide, and paclitaxel with or without filgrastim in treating women who have inflammatory or locally advanced breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG paclitaxel
- BIOLOGICAL filgrastim
- PROCEDURE surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2001-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016406
The ClinicalTrials.gov registry entry for NCT00016406 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 399 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00016406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016406 about?
NCT00016406 is a clinical study titled "S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without filgrastim in treating breast cancer. PURPOSE: Randomized phase III trial to compare the eff...
What is the current status of trial NCT00016406?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 399 participants. The study started on 2001-05. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00016406?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin (DRUG), paclitaxel (DRUG), filgrastim (BIOLOGICAL), surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00016406?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.